ECDC and the WHO Regional Office for Europe (WHO/Europe) recently concluded a crucial joint meeting focused on enhancing tuberculosis (TB) surveillance and monitoring across the WHO European Region.
Additional cases of Crimean-Congo haemorrhagic fever (CCHF), a potentially life threatening tick-borne viral disease, have been reported in the EU/EEA, according to new data published by ECDC. Experts have warned of an increased risk of transmission on the continent.
The purpose of this scoping review is to describe and summarise the rationale behind and methodological approaches used to conduct cascade-of-care analyses for TB infection in low-TB incidence countries.
Nearly 7,000 excess deaths from tuberculosis occurred in the WHO European Region in the three years of the pandemic from 2020 - 2022, compared to what experts had expected based on pre-2020 estimates.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.